Get the Stockscreener App
9.795
8.29%
-0.885
Passage Bio Inc stock is traded at $9.795, with a volume of 77,325.
It is down -8.29% in the last 24 hours and up +4.42% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$10.68
Open:
$10.5
24h Volume:
77,325
Relative Volume:
1.89
Market Cap:
$31.14M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-8.3718
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+6.35%
1M Performance:
+4.42%
6M Performance:
+2,169%
1Y Performance:
+1,151%
1-Day Range:
$9.72
$10.57
1-Week Range:
$9.125
$10.71
52-Week Range:
$0.257
$10.71
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
9.795 | 33.95M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG) - Defense World
Passage Bio (PASG) Price Target Increased by 21.85% to 40.39 - Nasdaq
What drives Passage Bio Inc stock priceGrowth Stock Opportunities & Affordable Investment Portfolio - earlytimes.in
How Passage Bio Inc. stock compares to industry benchmarksPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - Newser
Passage Bio Inc Stock Analysis and ForecastInstitutional Buying Trends & Capitalize On Fast Trends - earlytimes.in
Can Divgi TorqTransfer Systems Limited Compete Globally or Is It a Local Player OnlyDividend Reinvestment Plans & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Is Passage Bio Inc. stock a safe haven assetMarket Growth Report & Pattern Based Trade Signal System - Newser
Why Passage Bio Inc. stock is a must watch in 2025Market Rally & Free Community Supported Trade Ideas - Newser
Will Passage Bio Inc. stock sustain high P E ratiosEarnings Summary Report & Safe Entry Momentum Stock Tips - moha.gov.vn
Passage Bio to Present at Two Major Investor Conferences - MSN
Gains Recap: Why Passage Bio Inc. stock is seen as undervalued2025 Momentum Check & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Why Passage Bio Inc. stock is rated strong buyJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - moha.gov.vn
How currency fluctuations impact Passage Bio Inc. stockMarket Risk Analysis & Verified Stock Trade Ideas - moha.gov.vn
Risk Off: Will Passage Bio Inc. stock sustain high P E ratiosQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 - Defense World
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference - MyChesCo
Passage Bio (PASG) Price Target Decreased by 45.15% to 33.15 - MSN
Lucid Capital Markets initiates Passage Bio stock with Buy rating By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com India
Passage Bio, Inc. (PASG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How Passage Bio Inc. stock compares to market leadersInsider Selling & AI Powered Market Trend Analysis - newser.com
Is Passage Bio Inc. stock bottoming out2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MSN
How Passage Bio Inc. stock reacts to Fed rate cuts2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
What momentum shifts mean for Passage Bio Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
Chardan Capital Expects Reduced Earnings for Passage Bio - Defense World
Passage Bio Inc. stock trendline breakdownWeekly Trade Recap & Weekly Return Optimization Alerts - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
Using economic indicators to assess Passage Bio Inc. potentialQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
How Passage Bio Inc. stock reacts to global recession fearsEarnings Miss & Real-Time Volume Triggers - newser.com
Chardan Capital Raises Passage Bio (NASDAQ:PASG) Price Target to $21.00 - Defense World
Passage Bio (NASDAQ:PASG) Price Target Raised to $21.00 - Defense World
Can Passage Bio Inc. stock attract ESG capital inflowsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Fundação Cultural do Pará
Is Passage Bio Inc. stock a contrarian buyJuly 2025 Final Week & Weekly Stock Breakout Alerts - Fundação Cultural do Pará
What is Wedbush’s Forecast for Passage Bio FY2025 Earnings? - Defense World
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):